Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design
- 81 Downloads
Using parental FVB mice and their neu transgenic counterparts, FVBN202, we showed for the first time that dangerous hyperplasia of mammary epithelial cells coincided with breaking immunological tolerance to the neu “self” tumor antigen, though such immune responses failed to prevent formation of spontaneous neu-overexpressing mammary carcinoma (MMC) or reject transplanted MMC in FVBN202 mice. On the other hand, neu-specific immune responses appeared to be effective against MMC in parental FVB mice because of the fact that rat neu protein was seen as “nonself” antigen in these animals and the protein was dangerously overexpressed in MMC. Interestingly, low/intermediate expression of the neu “nonself” protein in tumors induced immune responses but such immune responses failed to reject the tumor in FVB mice. Our results showed that self–nonself (SNS) entity of a tumor antigen or danger signal alone, while may equally induce an antigen-specific immune response, will not warrant the efficacy of immune responses against tumors. On the other hand, entity of antigen in the context of dangerous conditions, i.e. abnormal/dangerous overexpression of the neu nonself protein, will warrant effective anti-tumor immune responses in FVB mice. This unified “danger-SNS” model suggests focusing on identification of naturally processed cryptic or mutated epitopes, which are considered semi-nonself by the host immune system, along with novel dangerous adjuvant in vaccine design.
KeywordsHER-2/neu Breast cancer Danger signal
This work was supported by the NIH R01 CA104757 grant (MHM) and flow cytometry shared resources facility, supported in part by the NIH grant P30CA16059. We gratefully acknowledge the support of VCU Massey Cancer Center and the Commonwealth Foundation for Cancer Research. We greatly appreciate Laura Graham in assisting us with adoptive T cell therapy. We thank Hooman Nikizad, Frances White and Julie S. Farnsworth for their assistance with flow cytometry. We also thank Dr. John Subjeck of Roswell Park Cancer Institute for providing us with the HSP110 expression vectors.
- 3.Burnet FM (1959) The clonal selection theory of acquired immunity. Vanderbilt University Press, NashvilleGoogle Scholar
- 4.Burnet FM, Fenner F (1949) The production of antibodies. 2nd edn. Macmillan and Company Limited, MelbourneGoogle Scholar
- 6.Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546–2553PubMedCrossRefGoogle Scholar
- 13.Khoruts A, Osness RE, Jenkins MK (2004) IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur J Immunol 34:1085–1090PubMedCrossRefGoogle Scholar
- 19.Makki A, Weidt G, Blachere NE, Lefrançois L, Srivastava PK (2002) Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun 16;2:4Google Scholar
- 23.Matzinger P (2004) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991–1045Google Scholar
- 32.Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, Bell AK, Ferrier RK, Sandilands GP, Gusterson BA (2004) Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res 6:R75–91PubMedCrossRefGoogle Scholar
- 34.Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T, Nakazawa M, Yura Y, Hamaoka T, Fujiwara H (2004) Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res 64:7588–7595PubMedCrossRefGoogle Scholar
- 35.Warger T, Hilf N, Rechtsteiner G, Haselmayer P, Carrick DM, Jonuleit H, von Landenberg P, Rammensee HG, Nicchitta CV, Radsak MP, Schild H (2006) Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 281:22545–22553PubMedCrossRefGoogle Scholar